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Open access under CC BYCharacterizing the biomolecular systems’ properties underpinning prognosis signatures derived from
gene expression proﬁles remains a key clinical and biological challenge. In breast cancer, while different
‘‘poor-prognosis” sets of genes have predicted patient survival outcome equally well in independent
cohorts, these prognostic signatures have surprisingly little genetic overlap. We examine 10 such pub-
lished expression-based signatures that are predictors or distinct breast cancer phenotypes, uncover their
mechanistic interconnectivity through a protein–protein interaction network, and introduce a novel
cross-‘‘gene expression signature” analysis method using (i) domain knowledge to constrain multiple
comparisons in a mechanistically relevant single-gene network interactions and (ii) scale-free permuta-
tion re-sampling to statistically control for hubness (SPAN – Single Protein Analysis of Network with con-
stant node degree per protein). At adjusted p-values < 5%, 54-genes thus identiﬁed have a signiﬁcantly
greater connectivity than those through meticulous permutation re-sampling of the context-constrained
network. More importantly, eight of 10 genetically non-overlapping signatures are connected through
well-established mechanisms of breast cancer oncogenesis and progression. Gene Ontology enrichment
studies demonstrate common markers of cell cycle regulation. Kaplan–Meier analysis of three indepen-
dent historical gene expression sets conﬁrms this network-signature’s inherent ability to identify ‘‘poor
outcome” in ER(+) patients without the requirement of machine learning. We provide a novel demonstra-
tion that genetically distinct prognosis signatures, developed from independent clinical datasets, occupy
overlapping prognostic space of breast cancer via shared mechanisms that are mediated by genetically
different yet mechanistically comparable interactions among proteins of differentially expressed genes
in the signatures. This is the ﬁrst study employing a networks’ approach to aggregate established gene
expression signatures in order to develop a phenotype/pathway-based cancer roadmap with the poten-
tial for (i) novel drug development applications and for (ii) facilitating the clinical deployment of prog-
nostic gene signatures with improved mechanistic understanding of biological processes and functions
associated with gene expression changes. http://www.lussierlab.org/publication/networksignature/
 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Since their conceptual inception in 2002 [1,2], clinical outcome-
tied molecular signatures in breast cancer have become a central
topic of research. Signatures for poor prognosis [2], recurrenceiomedical Informatics, 5841
0, USA. Fax: +1 773 702 2567.
u (Y.A. Lussier).
-NC-ND license.[3], invasiveness [4], and metastasis [5,6] have been experimen-
tally derived from patient groups and biological hypotheses. De-
spite the proliferation of signatures, genes constituting distinct
signatures exhibit poor genetic overlap (share few genes), even
though they paradoxically occupy a common prognosis space. They
are similarly efﬁcient in predicting bad clinical outcome in new co-
horts ‘‘raising questions about their biologic relevance, signiﬁcance
and clinical implication” [7,8]. A critical problem to solve for cancer
biologists and oncologists is whether these disjoint genetic signa-
tures can ‘‘jointly” provide a uniﬁed mechanistic insight on their
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outcome.
Clearly, the complexity of heterogeneity becomes a chief con-
sideration when trying to compare across signatures. As varied as
these gene signatures are, so too are the tissues and methods in
which they were derived. A sampling of tissue types evaluated
have included ER+ tissue [3], ER+/ER tumor specimens [6],
inﬂammatory breast carcinoma tissue [9], to cell lines [5]. Detec-
tion of gene expression changes have utilized standard commercial
gene chip platforms, to commercial customizable chips to in-house
cDNA spotted nylon microarrays [10] and RT-PCR assays [3]. Be-
sides the heterogeneity of probe designs, many of the legacy and
custom platform provide partial genome assessments in contrast
to the contemporary genome-wide arrays.
Aside from differences in molecular derivation, several hypoth-
eses have been postulated to explain the lack of overlap in the ge-
netic makeup of the signature. Arguments have included a case
made for inadequate patient sample size in developing the signa-
ture, or incomplete genome coverage, and secondly that although
the genes are different, they are merely separate aspects of the
same groups of molecular pathways or mechanisms. To overcome
the sample size restraint to a given original study, investigators
have demonstrated that pooling breast cancer data can enhance
classiﬁcation performance in 73% of the cases in one study or gen-
erate a signature that was comparable or superior to the prognostic
performance of the original signatures [11,12]. Examination of the
hypothesis of common molecular pathways hypothesis underlying
the genetic heterogeneity of gene signatures has been attempted
using straightforward Gene Ontology enrichment and failed to
demonstrate the functional overlap. For example, Van Vliet et al.,
note that there was less than 1% mean overlap of Gene Ontology
enrichment in their selection of breast cancer signatures [12]. More
recent efforts of pathway analysis have gone beyond the assess-
ment of Gene Ontology concordance. For instance, Pujana et al.
implemented a systems biology approach that does not rely on
gene expression data. By selecting four key biologically validated
breast cancer genes of distinct cancer-associated pathways, they
generated a network of 118 genes and 866 functional associations
capable of predicting the association of the hyaluronan-mediated
motility receptor gene (HMMR) with an increased risk of breast
cancer [13]. The success of this systems biology approach is seen,
too, in other methods such as that of genome-scale reverse engi-
neering of direct gene regulatory mechanisms which have been
developed using network modeling and successfully applied to
mammalian cells [14,15].
Meanwhile, we and other groups have developed comprehen-
sive protein–protein interaction (PPI) networks that have effec-
tively been used by our group and others to analyze protein
interactions underpinning share sub-phenotypes among otherwise
seemingly disparate diseases [16–18], and to characterize the func-
tion of a novel tumor suppressor microRNA [17]. In the context of
an individual expression signature in breast cancer, PPI networksTable 1
Ten breast cancer expression array signatures evaluated.
Phenotype measured by the signature Tissue used for derivation
Invasiveness [22] CD44+CD24/low cell lines vs. norma
Poor prognosis [1] (MammaPrint) Primary breast tumors
Metastasis [6] Primary breast tumors
PTEN/PIK3 pathway [10] Primary breast tumors
Node () disease recurrence [23] Primary breast tumors
Lung metastasis [5] Cell lines
Inﬂammatory breast cancer [9] (IBC_1) Primary breast tumors
Inﬂammatory breast cancer [19] (IBC_2) Primary breast tumors
Histologic grade [24] Primary breast tumors
Bone metastasis [25] Cell lineshave been effectively used to reanalyze gene expression data to de-
tect a subnetwork signature of metastatic disease [4] and more re-
cently used to predict prognosis [19]. Such studies demonstrate the
power of PPI networks to better understand complex molecular
disease processes at a systems level in single studies.
Further, experts in cancer network analyses have also recog-
nized the need to incorporate cancer-domain knowledge (con-
text-constraints) to network modeling [20,21]. We therefore
hypothesize that a context-constrained PPI network may be capa-
ble of connecting mechanistically heterogeneous signatures. As
most of the signatures were designed, in general, to distinguish
good vs. bad prognosis of clinical outcome or more speciﬁcally to
predict more aggressive disease progression, we posit that essen-
tial pathways such that of cell cycle regulation that is required
for oncogenesis as well as progression will correlate with a poorer
outcome. Bearing this in mind, in this paper we focus on develop-
ing a mechanistically transparent meta-signature of breast cancer.
We evaluate 10 breast cancer signatures published in leading jour-
nals (e.g. New England Journal of Medicine, Table 1) and ﬁnd their
interconnectivity in a cancer-context-constrained PPI network,
which we hope, could shed light on the underlying shared molec-
ular mechanisms of prognosis to the understanding of genetically
distinct gene expression signatures.2. Results
Evaluation of breast cancer signatures overlap: Consistent with
ﬁndings of previous analyses reported in the literature, we found
a slight overlap among various signatures. Out of the systematic
evaluation of each pair-wised combination of signature among
the 10 signatures of this study (45 combinations in total), seven
were found to share a few statistically signiﬁcant genes after
adjustment accounting for multiple comparisons [Fig. 1A, Supple-
mental Fig. S1]. However, none of the genes overlapped across all
signatures. Thus, as expected, we failed to identify the straightfor-
ward genetic overlap to connect different signatures. Additionally,
three signatures of metastasis (bone and lung metastasis signature,
respectively) formed a separate network aside from that of a
tightly nested web of cell cycle regulators, but were not statisti-
cally overlapping with the sparsely linked network of six other sig-
natures (eight inferred links between signatures in the inset).
Taking a pure network approach, we previously generated a
vast protein–protein interaction (PPI) network with 44,695 pro-
tein–protein interactions and 7321 proteins based on an integra-
tion of published databases [17]. The single protein analysis of
network (SPAN) [17] of breast cancer signatures were examined
based on direct interactions between two expression signatures
for each pair of signatures. Although some genes in the signatures
did interact directly among signatures, few of these associations
reached statistical signiﬁcance and only four signatures could be
directly related signiﬁcantly after adjustment with false discoveryNo. of genes Authors
l breast epithelium 186 Liu R, Wang X et al.
70 van ‘t Veer LJ, Dai H et al.
76 Wang Y, Klijn JG et al.
246 Saal LH, Johansson P et al.
16 Sotiriou C, Wirapati P et al.
54 Minn AJ, Gupta GP et al.
109 Bertucci F, Finetti P et al.
50 Van Laere S, Van der Auweral et al.
264 Ivshina AV, George J et al.
102 Kang Y, Siegel PM et al.
AB
Fig. 1. Analysis of breast cancer signature overlap using two different methodologies. (A) Direct statistical gene signature overlap with no inherent mechanistic meaning:
eight statistically signiﬁcant inter-signature connections were identiﬁed relating six of the 10 signatures [inset] based on genetic overlap (common genes between signatures)
after adjusting for the varying background of genes of the different expression platforms (adjusted p < 5%; cumulative hypergeometric distribution). The maximum number of
inter-signature connections for a single signature was 3. Signatures for lung and bone metastasis formed a separate unconnected network. Genetic overlap network did not
provide inherent mechanistic information. Gene Ontology enrichment identiﬁed proliferation pathway markers were strongly associated with increased histologic grade as
well as a worsened prognosis. (B) Inherent mechanistic and statistical overlap of genetic signature based on ‘‘breast cancer context”-constrained molecular interaction
networks: 16 statistically signiﬁcant inter-signature connections were identiﬁed relating 8 of the 10 signatures [inset] based on ‘‘breast cancer context”-driven network genes
that mechanistically anchor the signature overlap (red shapes). The Bonferroni adjusted p-value for the number of relationships to a single-gene network 60.05 (for the entire
network p < 0.01). The maximum number of inter-signature connections for a single signature was 5. Noteworthy, the inﬂammatory breast cancer did not signiﬁcantly
interact or overlap with the rest of the network. Legend: Red circles indicate genes derived from the expression signatures. Triangles represent genes derived from the breast
cancer context-driven network. Red hexagons are genes common to both expression signatures and the breast cancer context-driven network. Squares indicate phenotype of
gene signatures. Thin gray edges related genes to their respective gene signature (squares, A and B) and indentify any protein interactions in (A) (no statistics), and only
signiﬁcant gene interactions in (B) (adjusted p-values < 5%, Section 5, SPAN [16–18]). Thick blue edges of insets represent ‘‘inferred” statistical relationships between genes
signatures. Colors represent the following: red indicate genes from the breast cancer context-driven gene set; black indicates genes signiﬁcantly associated with more than
one gene signature (more than one phenotype); the remaining colors indicate separate signatures. Thus, a red hexagon indicates a gene found both in a signature as well as in
a breast cancer mechanism gene. Insets contain graphic representations of statistically signiﬁcant inter-signature connections. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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indirect interactions were considered using every intermediary
node in the network, only few indirect interactions among signa-
tures reached signiﬁcance due to the vast number of required
adjustments for multiple comparisons. Noteworthy, during our
permutation re-sampling of the network, we maintained the num-
ber of partners each protein had consistently in each iteration such
that our statistical analysis for the multiple comparisons was par-
ticularly stringent for hubs, while it allowed for higher sensitivity
in poorly connected nodes than a bootstrap method. In other
words, the node degree of each protein is equal to that of the ob-
served distribution in each simulated network. However, while
some signiﬁcant genes were shown to interact more than expected
by chance between less than half the breast cancer signatures, this
type of analysis was not constrained with biological contexts thus
molecular mechanisms derived from such modeling might not be
relevant to cancer biology.
Hypothesizing that non-cancer related nodes in our PPI network
were generating background interaction noise or simply reducing
the power of the statistical analysis due to the multiplicity of com-
parisons, we improved our network model by developing a ‘‘breast
cancer context”-constrained PPI network using known literature
knowledge about breast cancer. As described in Section 5, we used,
as inter-signature nodes, 250 cancer-related genes curated from
the literature that were previously identiﬁed by Paik et al. [3] in
the New England Journal of Medicine. The biological and patho-
physiological causal mechanistic role of these 250 breast cancer
genes were selected by traditional in vitro and in vivo biological
studies. Examining SPAN networks between each mechanistically
derived breast cancer gene and each signature, and after correcting
for multiplicity and for node degree (Section 5 on the permutation
re-sampling [17]), 54-genes (what we are deﬁning as the network-
signature) were found to be signiﬁcantly more connected than by
empirical distribution (adjusted p < 5%) and were inherently mech-
anistically anchored (Table 2). Each single protein connectivity ofTable 2
54-Gene composing the network-signature. Breast cancer constrained SPAN network m
evaluated the PPI network property of each gene: H = hub gene, B = bottleneck gene, H/B
Statistically signiﬁcant genes of the network-signature
APC (H) CDC2 (B/H) GINS2
AURKA (H/B) CDC20 (H) ITGA5 (H)
AURKB (H/B) CDC25B MAD2L1 (H)
BUB1 CDC6 (H) MAP4
BUB2 CDC7 (H) MCM2 (H)
CCNA2 CDKN1A (H/B) MCM6 (H)
CCNB1 (H) CDT1 (H) NEK2
CCNB2 FBXO5 ORC6L (H)
CCNE2 GINS1 PAK3 (H)
Table 3
Gene ontology enrichment of network-signature genes.
GO ID Function name
GO:0007067 Mitosis
GO:0007049 Cell cycle
GO:0051301 Cell division
GO:0006260 DNA replication
GO:0006270 DNA replication initiation
GO:0007051 Spindle organization and biogenesis
GO:0048015 Phosphoinositide-mediated signaling
GO:0006268 DNA unwinding during replication
GO:0000079 Regulation of cyclin-dependent protein kinase activity
GO:0007089 Traversing start control point of mitotic cell cycle
GO:0000082 G1/S transition of mitotic cell cycle
*The signiﬁcant biological processes were identiﬁed by comparing genes in PPIS and Affy
at 0.01 with enrichment calculated using the cumulative hypergeometric p-value adjusthe deduced molecular mechanisms of breast cancer signature
was independently tested within each signature and corrected
for multiple comparisons. Thus, the observed interconnectivity
among signatures arose from shared intrinsic molecular mecha-
nisms rather than from inherent computational/statistical design
to connect signatures. In particular, seven breast cancer context
genes effectively anchored the inter-signature connections:
CCNB1, APC, CDC20, MCM3, CDKN1A, COL1A1, and NEK2 (Fig. 1B,
red nodes), and were highly enriched for cell cycle- and cellular
movement-dependent involvement in G2/M DNA damage check-
point regulation along with ATM signaling based on Ingenuity
Pathway Analysis [26]. Sixteen signiﬁcant inter-signature relation-
ships were identiﬁed between eight of the 10 signatures, including
the two-metastasis signatures that could not be connected using
simple statistical enrichment (Fig. 1B). Fifteen of the 54 network-
signature genes were found to connect at least three gene signa-
tures. Consistent with our prior gene overlap method, lung and
bone metastasis were connected to one another; but, this time,
they also connected to other signatures via their signiﬁcant inter-
action with the node(+) disease recurrence signature. Moreover,
ﬁve signatures were each independently connected to ﬁve other
signatures demonstrating an extremely tight, intertwined web of
interconnectivity (Fig. 1B). Noteworthy, genes of the inﬂammatory
breast cancer signatures IBC-1 and IBC-2 were the only genes that
did not interact signiﬁcantly with the 250 breast cancer-related
genes.
Gene Ontology enrichment studies identiﬁed these genes to be
predominantly regulators of the cell cycle pathway (Table 3). For
example, cell cycle (GO:0007049) was annotated with 25 of the
54-genes (adjusted p = 0.4  1011). Similarly, cell division
(GO:0051301) and mitosis (GO:0007067) ranked highly. Corrobo-
rating these observations using separate software, the Ingenuity
Pathway Analysis also revealed enrichment of the 54-genes in
the network-signature represented in multiple canonical pathways
involved in cell cycle regulation. In particular, the top 6 Ingenuityodeling identiﬁed 54-genes associated with the breast cancer mechanism. We also
= hub and bottleneck gene (Section 5).
PCNA (H/B) CCNE1 (H) MCM10 (H)
PSMD12 (H) CDK7 (H) MCM3 (H)
PSMD2 (H) COL1A1 (H) MCM4 (H)
PSMD7 (H) CREBBP (H/B) MMP2
PTTG1 (H) DBF4 (H) ORC3L (H)
STAT1 (H/B) E2F3 PAK1 (H/B)
TGFBI (H/B) E2F5 PLCG2 (H)
TSG101 FN1 (H) SPARC
AKT1 (H/B) KNTC2 SYK (H/B)
Network-signature genes GO term genes Adjusted p-value*
15 128 3.8E11
25 306 3.8E11
18 160 3.8E11
11 102 4.5E11
5 19 9.6E07
4 7 9.6E07
5 26 4.6E06
3 11 7.6E04
4 37 9.4E04
2 5 9.8E03
3 28 1.5E02
metrix U133a chips using Onto-Express software. The criterion of signiﬁcance is set
ted for multiple testing.
J. Chen et al. / Journal of Biomedical Informatics 43 (2010) 385–396 389pathways identiﬁed included: mitotic roles of polo-like kinase, cell
cycle G2/M DNA damage regulation, molecular mechanisms of
cancer, CHK proteins in cell cycle regulation, G1/S checkpoint reg-
ulation, and cell cycle control by BTG family protein.
2.1. Network properties of the 54-genes
To establish whether these 54-genes coded for proteins that in-
deed contained distinct network properties, we identiﬁed ‘‘hub”
proteins vs. ‘‘bottleneck” proteins as described by the Gerstein re-
search group [27] over the entire PPI. Gerstein et al. deﬁned hubs
as proteins that have the 20% highest number of neighbors and
bottlenecks as the proteins that are in the top 20% in terms of
betweenness (connecting groups of proteins). Hub and bottleneck
can occur independently of one another. In contrast, of the 54-
genes that we selected, 37 (69%) were hub proteins among which
11 (30%) were also bottleneck proteins. This is far in excess of
the baseline, thus indicates the central interacting role that these
genes may play in the context of breast cancer networks.
As a separate ‘‘signature” validation of our approach, we exam-
ined the direct overlap of our 54-gene network-signature with an
independent 168-gene ‘‘signature of proliferation” based on a clus-
ter of gene associated with in vitro oncogenesis [28]. This cluster of
genes centered around p53 and INK4A signaling pathways that had
been demonstrated in historic datasets to be associated with poor
prognosis – similar to that of the evaluated signatures. Interest-
ingly, in total, 14 out of 168 genes signiﬁcantly overlapped with
the 54-gene network-signature (p-value < 5%).
2.1.1. Validation of the prognostic potential of the 54-gene from the
network-signature
We tested the network-signature in three separate genome-
wide microarray datasets comparing breast cancer patients out-
come: GSE7390 (198 patients), GSE4922 (249 patients) and
GSE2990 (189 patients), were downloaded from NCBI GEO data-
base and analyzed in the same way for independent validation
[23,24,29]. Two datasets were used in the generation of the origi-
nal expression signatures (histologic grade and node-negative
recurrence) along with a third independent dataset that had been
used as a separate validation for the node-negative signature.
The third dataset thus could be used to conﬁrm the validity of
the network-signature. Time to recurrence was used for GSE7390
data analysis. Time to distant metastasis was used for the analysis
of the remaining two datasets, as the original gene signatures de-
rived from GSE4922 and GSE2290 did not assess this clinical
endpoint.
We ﬁrst explored the relationship between the network-signa-
ture genes and pathologic parameters using hierarchical clustering
and GSEA. The 198 patients in GSE7390 were classiﬁed into two
clusters. Via chi-square testing, one cluster was found to be en-
riched with disease advanced and more aggressive tumors includ-
ing pathological features of ER (p < 0.0001), pathological grade 3
(p < 0.0001), and lymph node inﬁltration stage 3 (p = 0.0405). How-
ever, there was no signiﬁcant difference in time to recurrence be-
tween the two clusters (Supplemental Fig. S2 Logrank p = 0.394).
The majority of the network-signature genes demonstrated higher
expression levels in ER than in ER+ samples (Supplemental Figs.
S3–S5). Twenty-nine out of the 54 network-signature genes were
expressed consistently and signiﬁcantly (Student’s T-test p-va-
lue < 0.05) higher in ER than ER+ samples across all of the three
microarray datasets (Supplemental Table S1).
We then examined a GSEA comparison between ER+ vs. ER
samples, high vs. low grade, poor vs. good prognostic samples de-
ﬁned by conventional prognostic tools: Adjuvant!Online, St. Gallen
and Nottingham Prognostic Index (NPI). Again, as observed in the
datasets described above, GSEA showed that only the network-sig-nature demonstrated an overall upregulation of signature gene
expression in ER() samples (FDR = 0), while none of the conserva-
tively selected control gene sets demonstrated signiﬁcant upregu-
lation in ER() samples. Similarly, in the GSE7390 dataset,
overexpression of the network-signature genes was found in the
poor prognostic samples predicted by the aforementioned conven-
tional tools (FDR = 0) and also the high-grade samples.
These prognostic scores were not available in GSE4922 and
GSE2290, and thus cannot be veriﬁed in these two datasets. Kap-
lan–Meier plot revealed that the high and low risk groups deter-
mined by network-signature did not show strong signiﬁcant
different outcome in the three datasets (Supplemental Fig. S2).
After gaining a better understanding of the clinical correlations,
we then examined the utility of the signature for prognostication.
We noted that the network-signature alone was not predictive for
the clinical outcome in the datasets tested (Logrank p-value 0.22
for GSE7390, 0.05 for GSE4922 and 0.07 for GSE2290). However,
multivariate analysis demonstrated that the network-signature
with ER status as a covariate, successfully predicted two-risk
groups that displayed signiﬁcant different outcome in all of the
three datasets (Fig. 2A–C). The Logrank p-value was 0.02 for
GSE7390, 0.02 for GSE4922 and 0.03 for GSE2290. In contrast, ER
status alone failed to provide an independent prediction of clinical
outcome (p = 0.22 for GSE7390, p = 0.53 for GSE4922 and p = 0.20
for GSE2990) consistent with clinical observations demonstrating
the insufﬁciency of ER status alone to provide accurate prognosis.
However, pathological grade as a covariate with the network-sig-
nature failed to predict the outcome (data not shown).
Therefore, multivariate analysis of the network-signature with
ER status, but not the network-signature or ER status alone accu-
rately predicted the clinical outcome of the heterogeneous popula-
tion of breast cancer patients without the requirement of extensive
machine learning.
The network-signature was also evaluated for its prognosis of
ER+ stratiﬁed samples by univariate analysis. The Logrank p-value
of the ER+ samples was 0.02 for GSE7390, 0.02 for GSE4922 and
0.03 for GSE2990 (Kaplan–Meier curve shown in Fig. 2D–F). Thus,
the prognostic power of the network-signature maintained among
ER+ patients. Therefore, the network-signature demonstrated the
potential to stratify the therapeutically responsive ER positive pa-
tients into high and low risk groups that will have distinct clinical
outcomes measured by survival. This prognostic stratiﬁcation po-
tential of the network-signature has signiﬁcant clinical implica-
tions since it could help to identify the high-risk patients for
additional and more aggressive therapeutic intervention prior to
disease progression.
2.2. Overlay of the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways
To understand the interplay and biology of the 54-gene net-
work-signature, we calculated the statistical signiﬁcance of pro-
tein–protein interaction (PPI) among these 54-genes using SPAN
(Section 5 and [17]) and organized the interactions according to
their connectivity relationship with the respective prognostic sig-
nature (Fig. 3, Section 5 and [30]). Thereafter, we conducted func-
tional enrichment analysis of KEGG pathways [31] and overlaid the
statistically prioritized four KEGG functions (cell cycle, p53 signal-
ing, ErbB2 signaling and focal adhesion) onto the PPI gene interac-
tion map (Fig. 3, color coding for different KEGG pathway
function). The resultant visualization in Cytoscape facilitated more
readily an appreciation of the mechanistic underpinning associated
with each signature and the overlap we identiﬁed via PPI modeling.
For example, ‘‘focal adhesion” KEGG pathway linked ‘‘bone
metastasis”, ‘‘lung metastasis” signature and ‘‘Node() disease
recurrence” signatures via COL1A1, which is one of the seven in-
Fig. 2. Kaplan–Meier analysis of the 54-gene network-signature in three historical GEO datasets. Endpoints: time to recurrence was used for breast cancer microarray
GSE7390 [23], time to distant metastasis was used for GSE4922 [24] and GSE2290 [29]. Multivariate analysis with ER status as a covariate successfully predicted two-risk
groups that displayed signiﬁcant different outcome in all of the three datasets (Fig. 2A–C). The Logrank p-value was 0.02 for GSE7390, 0.02 for GSE4922 and 0.03 for GSE2290.
Univariate analysis of ER(+) samples demonstrated a Logrank p-value of the ER+ samples was 0.02 for GSE7390, 0.02 for GSE4922 and 0.03 for GSE2990 (Fig. 2D–F).
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(Fig. 1B). Another example is CDKN1A (p21), which was also iden-
tiﬁed by context-driven gene analysis and a negative regulator of
cell cycle. It was a multifunctional node (cell cycle/ErbB2/focal
adhesion, Fig. 3) that connected the cluster of three metastasis
gene signatures anchored by COL1A1 to the ‘‘histologic grade”
signature and the ‘‘invasiveness” signature. Additionally, we ob-served a strong overlap of PPI-genes shared between the ‘‘poor
prognosis” signature and ‘‘histologic grade” signature. Such ob-
served molecular pathway overlaps in PPI network provided a
mechanistic explanation of a well-documented histologic observa-
tion of high incidence of metastasis and poor prognosis associated
with high-grade tumors. Therefore, COL1A1, CDKN1A and MCM3
and their direct interacting genes could be further tested and char-
hsa04110    Cell cycle
hsa04115    p53 signaling pathway
hsa04012    ErbB signaling pathway
hsa04510    Focal adhesion
Expression signature genes
Cancer genes from context-driven network 
Both expression signature gene and context driven
Expression signature
Lung
metastasis
Bone
metastasis
Node(-)
disease
recurrence
Invasiveness
Histologic
grade
Poor
prognosis
PTEN
pathway
Metastasis
Fig. 3. 54-Gene breast cancer network-signature overlaid with KEGG pathway. We evaluated the connectivity of the 54-gene breast cancer network-signature to itself
through permutation re-sampling of the PPI controlling for hubness. Nodes which had an empiric p-value of <0.05 were retained. KEGG pathways cell cycle, p53 signaling,
ErbB2 signaling and focal adhesion were then overlaid onto the network facilitating a visual ‘‘roadmap” among signatures (squares), breast cancer signatures (circles), and
breast cancer background genes (triangles). Breast cancer signature genes that were also included in the breast cancer background gene list are represented by hexagons. For
example, multifunctional node CDKN1A (cell cycle/ErbB2/focal adhesion) connects the cluster of three metastasis gene signatures anchored by COL1A1 to the ‘‘histologic
grade” and ‘‘invasiveness” signatures.
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can be used for patient stratiﬁcation for more personalized treat-
ment. Collectively, these observations have demonstrated the sig-
niﬁcant functional overlaps among the 54 mechanistic network-
signature genes and the molecular underpinning of the association
between high histologic grade and high incidence of invasiveness
or/and with poor prognosis.
3. Discussion
In this study, 10 breast cancer signatures are essentially
mapped onto a protein–protein interaction network of known can-
cer molecules. Although previous papers have noted that these
breast cancer signatures appear to be genetically ‘‘disjoint” – we
have found a signiﬁcant degree of mathematical overlap among
signatures which nonetheless failed to provide mechanistic under-
standing (Fig. 1A). In contrast, we employed a networks approach
in which we regard different signatures not in isolation, but in
totality, as a vast interconnected array of causal and non-causal
molecules associated with breast cancer state and interrelating
through canonical molecular pathways (Fig. 1B; Table 1; Fig. 3).
The 54-genes are in essence prioritized genes via statistical enrich-
ment of shared biomolecular systems properties of the aggregate
molecular signatures that also have phenotypic/prognostic associ-ations. Indeed, we propose that a mechanistic overlap vis-à-vis
pathway allows the researcher to ‘‘do more with less”. Whereas
in the simple statistical overlap method yields only seven gene-
mediated signiﬁcant inter-signature relationships (Fig. 1A inset),
our context-constrained pathway overlap methodology is able to
ﬁnd twice the number of signiﬁcant relationships between signa-
tures using far fewer genes (Fig. 1B inset). Also biologically inter-
esting are the gene signatures that did not connect in our SPAN.
Inﬂammatory breast cancer (IBC) histologically, clinically and
molecularly behave different than traditional ductal adenocarcino-
mas [32]. Researchers are beginning to develop targeted treatments
for this subtype and our results – given the lack of connectivity of
either IBC-1 or IBC-2 signatures to the PPI network – are consistent
with the belief that mechanisms of IBC progression are different
(Table 1, Fig. 1B).
From an informatics perspective, traversing the generated PPI
network deeper than the ﬁrst interactor generates noise and re-
duces the ability to ﬁnd signiﬁcance. In contrast, a carefully se-
lected ﬁrst interactor causally associated to breast cancer in the
network provides computational relevance and consequently
statistical power beyond ﬁrst interactors between breast cancer
signatures. In other words, connecting the gene of a ﬁrst signature
to that of second signature via an intermediate breast cancer
interactor corresponds to connecting a second level interactor in
 Imputed pathways 
Unknown pathways 
Molecular 
Signature 
 Network Signature 
Context-Constrained
PPI Network
Known mechanisms
Fig. 4. Model for understanding molecular signatures: Illustrated in this ﬁgure is
the derivation of the 54-gene network-signature that can be conceived as a subset
of the ‘‘known mechanisms” of context-constrained networks (top orange compo-
nent). Molecular signatures can be thought as mapping to different portions of a
network. The ‘‘known mechanisms” portion overlay well on top of experimentally
determined protein interactions in the laboratory. The ‘‘imputed pathways”
corresponds to poorly described associations in the PPI network and due to their
lack of characterization can be mistaken for background noise of the network. The
‘‘unknown pathways” portion of the gene signature refers to molecular interactions
that may not be in the network. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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ally associated with breast cancer. As a result, signature genes sta-
tistically connected to causal breast cancer genes more than
expected by conservative statistical controls thus become explicit
interactors of a known breast cancer mechanism. We also recapit-
ulate a well-established issue by bioinformaticians involved in the
analysis of protein interaction networks: cellular context matters;
unexpressed proteins contribute to noise in a context-independent
PPI.
The ability of the 54-gene signature to predict poor outcome in
breast cancer reassures the validity of our network approach in
understanding gene signatures. Moreover, its signiﬁcant overlap
with 168 mechanistically selected genes in a model of tumorigen-
esis conﬁrms that indeed that we are capturing underlying
pathway deregulation associated with oncogenesis [28]. This pre-
diction is obtained from 54-genes of the signatures that can com-
prise as many as 250 genes and are often derived from intensive
machine learning algorithms in the absence of conducting machine
learning of outcome datasets.
However, the network-signature required ER status to assist in
predicting clinical outcome in the heterogeneous breast cancer
populations. It is possible that the published gene signatures are
intrinsically biased toward ER(+) tumors because they were gener-
ated using heterogeneous patient data which was primarily ER(+).
Indeed, ER(+) breast cancer comprises 70% of breast cancer patients
[33] and ER status alone is known incapable of predicting survival
in these populations. Although ER status provides a useful treat-
ment target, ER speciﬁc gene markers can be equally found in sig-
natures that correlate with both good and poor prognosis [34].
Another possibility is that this 54-gene network-signature and
the ER status lacked the statistical power alone to show survival
prediction and requires their joint utilization to reach signiﬁcance
in non-stratiﬁed heterogeneous populations we analyzed. How-
ever, in a stratiﬁed population of ER positivity, the mechanistic net-
work-signature has the independent prognostic power to further
stratify patients into the high and low risk groups that have dis-
tinct clinical outcomes.
Clinically, the proposed 54-gene network-signature and the
resulting PPI subnetwork are invaluable for understanding the role
of existing gene signatures. In particular, the van ‘t Veer et al. 70-
gene signature (MammaPrint, see ‘‘poor prognosis” in Table 1
and Figs. 1 and 3) [1] which has been validated in clinical trials
as an excellent independent marker of prognosis [35] is more clo-
sely related (Fig. 3) to the gene signatures of histological grade and
invasiveness. While highly enriched in cell cycle genes, Mamma-
Print (poor prognosis) did not connect to the bone or lung metas-
tasis signatures that appear to be mediated by cellular adhesion as
noted by the KEGG pathway enrichment. The conclusion we may
draw is that although MammaPrint and these other signatures
(some of which have been validated in other tumor types) map
to the same prognostic space, they are in part mechanistically com-
plimentary as they poorly overlapped with the genes in our net-
work. Prospective clinical studies are required whether network-
signature, such as the one we report will be more effective at pro-
viding stratiﬁed molecular diagnosis or/and prognosis.
From a practical clinical practice standpoint, our methodology
elucidates similarities and differences among signatures and points
us toward potential biomarkers that may help us determine the
choice of treatment. Tantalizing are highly- connected highly genes
such as COL1A1 that sits on the intersection of bone metastasis,
lung metastasis, and node() recurrence. Unsurprisingly, it is
tagged with the KEGG pathway as being part of focal adhesion. Pre-
vious researchers have noted that this gene is highly overexpressed
in a meta-analysis of 13 publications [36]. However, no further re-
search has been performed to evaluate its utility as a prognostic
marker. With our network, the KEGG mechanism associated withCOL1A1 and its placement in our network makes for a clearer pic-
ture of the gene’s phenotype and prevents a convincing case for its
potential as a functional biomarker. One may speculate that alter-
ation of the focal adhesion pathway as evidenced by an alteration
in COL1A1 expression leads to detachment of the breast cancer
cells from the host environment and increase the possibility of dis-
tant metastasis. Targeting this gene then, may ultimately maintain
regional control.
In essence, interaction networks, such as Fig. 3, provide the cli-
nicians with a more synthetic and mechanistic visualization to
understand gene expression changes associated with breast cancer
prognostication, and to facilitate the design of most appropriate
combinations for personalized cancer treatment. We view contem-
porary clinical stratiﬁcation of patients using ER, PR, and HER2 sta-
tus as the beginnings of a rudimentary road map, a preamble for
individualized drug selection.
In 2007, Massague et al. commented on the necessity to explore
the mechanisms of the shared prognosis space between disjoint
signatures [8]. Based on our computational modeling and valida-
tion using clinical datasets, we propose a model (summarized in
Fig. 4) that provides, the ﬁrst systems-based explanation for a sub-
set of signature genes that determines the mechanistic makeup of
genetically diverse gene signatures. These observations suggest
that each network-based molecular signature is likely associated
with one or more aspects of a large protein–protein network. First,
they may recapitulate known portions of canonical pathways or
identify new signiﬁcant relationships augmenting the known path-
ways. The second portion of the signature, that we have been
deeming the ‘‘noise” may very well contain vital oncogenic path-
ways that remain to be characterized for their roles in cancer
and their relationships with the canonical pathways. And the third
aspect is that naturally there may be intermediary/interacting
molecules that have yet to be characterized rounding out the ‘‘un-
known” portion of the molecular signature.
3.1. Limitations
We are beholden to the data we use as our SPAN constraint as
much as we are beholden to the databases we used to generate
the SPAN which consisted of both eukaryotic and prokaryotic data.
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could grow with increasing data and knowledge. We intend to re-
run our analyses at a future time points with more carefully se-
lected gene signatures and a more informed constraint. Indeed,
because of the constraint we selected, a clinical limitation of our
analysis was that we were not able to include the 21-gene signa-
ture that has been commercialized as OncotypeDX [37] which is
a popular test available in the United States. These genes 21 genes
were not derived from expression analysis but rather from the 250
Paik genes that we used as our contextual genes with causal asso-
ciations to breast cancer. Consequently, our statistical analysis
would have been inherently biased. Future studies using a different
context-constraint will be required to evaluate the OncotypeDX
and MammaPrint overlap.
A computational limitation of our approach is that there may be
other valuable intermediaries, but the multiplicity of comparisons
required to evaluate every single protein of the PPI reduces the
greatly the statistical power. An alternate approach could have
used a metanalysis of expression arrays of breast cancer and nor-
mal tissue to identify on a genome-wide basis, which subset of
the network should be explored rather than relying on a well-
acknowledged set of genes from the review of literature. More
complex methods for aggregation of nodes in protein interaction
networks can identify patterns beyond the immediate interactor
and should be explored in future studies.4. Conclusion
Weprovide a novel demonstration that genetically distinct prog-
nosis signatures, developed from independent clinical datasets,
inherently occupy overlapping prognostic space of breast cancer
via shared mechanisms that are mediated by genetically different
yet mechanistically comparable interactions among proteins of
differentially expressed genes in the signatures. This is the ﬁrst
application of a network-based approach to aggregate established
gene signatures in developing a phenotype/pathway-based cancer
roadmap with a potential (i) for prospective applications in drug
development and (ii) for elucidating molecular mechanisms under-
pinning dissimilarmolecular proﬁles sharing interchangeable prog-
nostic capabilities.5. Methods
5.1. Signatures (Table 1)
A total of 10 gene expression signatures were examined in this
study. This included signatures from Minn et al. [5], Liu et al. [22],
Wang et al. [6], Bertucci et al. [9], Ivshina et al. [24], Kang et al. [25],
Saal et al. [10], Sotiriou et al. [23], van ‘t Veer et al. [1], and Van
Laere et al. [19]. Genes comprising each of the signatures were ta-
ken from each of the papers or their supplementary materials and
translated into a representative set of SwissProt identiﬁers using
the DAVID tool [12]. The original genes, translation tables (where
needed), and results are available on http://www.lussierlab.org/
publication/networksignature/.5.2. Gene overlap analysis between two signatures
The SwissProt translated signatures were analyzed for overlap
using a Perl script comparing the accession numbers of the genes
in each signature. A similar technique was used to test for connec-
tivity through the combined interaction network. Accession num-
bers from pairs of signatures were matched to the proteins in the
network and analyzed to determine connectivity between proteins.Eq. (1) allows us to formally calculate the statistical signiﬁ-
cance of overlapping genes between two expression signatures.
Variable ‘N’, the common background genes, represents the total
number of genes overlapping between the total probes of chips
used in two studies. Variables M and n are the number of genes
of the two compared expression signatures. Variable m corre-
sponds to the number of genes that are found to overlap
between the two compared expression signature (M \ n). Genes
of each array were translated in standard HUGO gene identiﬁers.
Translation of non-standard arrays of the older studies required
manual revision of hundred of probes with non-standard
probes.
PðiP mjN;M;n;mÞ ¼
Xn
i¼m
M
i
 
NM
ni
 
N
n
  ð1Þ
Results are adjusted to account for multiple testing using the Dunn-
Sidak adjustment, a Bonferroni-like method. In Eq. (2), p0 and p rep-
resent the corrected and uncorrected p-values, respectively, and n
represents the number of independent comparisons in the study.
The resulting statistically signiﬁcant connections were drawn using
Cytoscape [30].
p0 ¼ 1 ð1 pÞn ð2Þ5.3. Generation of the protein–protein interaction (PPI) network from
multiple databases
As we described in a previous publication, the protein–protein
interaction network was generated by integrating six protein inter-
actions and signaling datasets [16–18]. In brief, protein interac-
tions from each dataset were standardized to a two-column list
of pairwise interactions and merged into a non-redundant interac-
tion network. Identiﬁers were converted to a common SwissProt
standard coding using translation tables from HUGO and the data
sources’ own cross-mappings. We only included interacting pairs
that were generated from physical experiments using methods
other than the yeast two-hybrid or dosage rescue. Imputed interac-
tions were not used. Datasets included BioGRID 1 [38], Reactome
[39] DIP data [40], MINT [41] Human Proteome Reference Database
6 (HPRD) [42], BIND [43].5.4. Single Protein Analysis of Networks (SPAN [17]), a conservative
permutation re-sampling of the PPI
Permuted PPI networks were generated using a link randomi-
zation approach [44]. Proteins are considered as nodes and inter-
actions between proteins are links. Since biological networks are
scale-free rather than random [45], link randomization can create
conservative ‘‘permuted networks” as controls, from which we
can derive an empirical distribution of interactions between a
subset of proteins. Furthermore, our implementation of a link-
randomization conserves the number of ‘‘connections” of each
speciﬁc protein (node-degree) [45]. Thus the scale free properties
of the original distribution are preserved in every permutation as
well as the node degree of each speciﬁc protein, a distinctive and
highly conservative approach that we previously published [17],
while the interactions (links) between these proteins vary. Self-
interactions, such as those formed by homomultimers, were ig-
nored to avoid introducing bias into the network. Duplicate pro-
tein interaction pairs were also excluded in the permutation.
Ten thousand of these permuted networks were generated from
the original amalgamated interaction network consisting of real
datasets.
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signatures
This previous network was used for calculating the false discov-
ery rate (FDR) of direct connectivity between each genes of each
pair of signatures (based on the number of direct protein interac-
tors between the two signatures). FDR was calculated based on
the median number of direct interactions between the two signa-
tures in the empirical distribution divided with the observed num-
ber of interactors. First direct interactions were compiled and
analyzed, then indirect interactions with one intermediary node
as a separate analysis.
5.6. Gene interaction between an expression signatures genes and
breast cancer genes to infer interaction (mechanistic overlap) between
signatures. Context-knowledge constrained PPI network: Single Protein
Network Modeling and prioritized PPI in cancer
Additionally, we developed a model that estimates the proba-
bility of occurrence of an observed Single Protein Network arising
from the connectivity of a protein to a list of known proteins de-
rived from a well-established list of 250 breast cancer genes man-
ually curated from the literature and published in the New England
Journal of Medicine [3]. The observed number of interactions be-
tween the breast cancer signatures and the breast cancer genes
can thus be derived and compared to expected distribution from
the previously described permutation re-sampling. The unadjusted
p-value of each signature gene connectivity is further adjusted for
multiplicity using Bonferroni-type adjustments (the number of
genes in each breast cancer signature = the total number of com-
parisons). A similar procedure was developed to calculate the con-
verse: each single gene in the breast cancer genes was analyzed for
its number of interactions with the total lists of genes in each of the
breast cancer signatures independently and assigned an adjusted
p-value (in this case, controlled for 250 analyses in the gene list).
Since breast cancer signatures were independently generated by
different authors from distinct cohorts of patients – there were
no additional adjustments of p-values for multiplicity between
studies of each signature as each signature analysis was considered
independent from one another. Thereafter, each breast cancer sig-
nature gene that met an adjusted p-value < 5% was retained as well
as its connected genes from the set of 250 and the converse (since
there were two single protein network analyses). The statistically
signiﬁcant single-gene networks were simply assembled in a joint
network to show shared mechanisms (breast cancer genes known
mechanistically to affect the biology of breast cancer). The result-
ing network was drawn using Cytoscape [30]. It is important to
note that in each meticulous permutation we perform, each pro-
tein retains a constant node degree. To attain a signiﬁcant p-value,
highly connected proteins are thus required to surpass an equally
well-connected protein in the permutation. This non-trivial per-
mutation thus controls well for hubs – and is more sensitive to de-
tect increased connectivity of poorly connected proteins than a
straightforward bootstrap.
5.7. Permutation re-sampling of networks
Permuted networks were generated with a Perl script that shuf-
ﬂed the connectivity of the nodes in the network while maintain-
ing their node degree as well as the distribution of node degree
in the network. Ten thousand of these permuted networks were
generated from the original amalgamated interaction network.
These networks were then used to connect the proteins of the
molecular signatures in a permutation re-sampling. This procedure
yielded connectivity distributions at two scales. First, we derived a
total connectivity distribution for each signature as a whole whenrepeatedly reconnected to the set of poor-prognosis candidates. At
a smaller, more granular scale, we derived a distribution for each
protein in the signatures considered in the study.
5.8. Gene expression datasets
Microarray Data source for validation of protein–protein inter-
actions and all breast cancer microarray datasets using the same
genome-wide platform (Affymetrix U133A chip) with available
.cel ﬁles and clinical parameters in NCBI GEO database were down-
loaded and cell lines were downloaded as referenced prior.
5.9. Gene expression software
Bioconductor GCRMA package [46], dChip [47], BRB-ArrayTools
[48] and GSEA [49] software were used for microarray data analy-
sis. GraphPad prism 4.03 for Windows [50] was used for Chi-
square test, Kaplan–Meier plotting and Logrank test. Onto-Express
[51] was used for Gene Ontology (GO) analysis.
5.10. Identiﬁcation of biological processes and canonical pathways
enriched with the network-signature
The functional proﬁles of the PPI-signature genes were repre-
sented by the biological processes in the Gene Ontology (GO) data-
base [52] or signaling pathways with the number of PPI-signature
genes in each GO category or pathway compared to that in the
Affymetrix U133A chip to determine the signiﬁcance function.
The analysis of biological processes was performed using Onto-Ex-
press, with the default selection of statistical method (hypergeo-
metric distribution followed by Benjamini-Hochberg false
discovery rate correction). The lists of the network-signature genes
were uploaded into Onto-Express to identify signiﬁcant biological
process (corrected p-value < 0.01).
Disregulated genes were uploaded into the Ingenuity Pathway
Analysis (IPA) tool from Ingenuity Systems. The genes mapped to
corresponding gene objects in the IPA tool are called ‘‘focus genes.”
The signiﬁcance of a canonical pathway is controlled by p-value,
which is calculated using the right-tailed (referring to the overrep-
resented pathway) Fisher Exact Test for 2  2 contingency tables.
This is done by comparing the number of ‘Focus’ genes that partic-
ipate in a given pathway, relative to the total number of occur-
rences of those genes in all pathways stored in the IPKB. The
signiﬁcance threshold of a canonical pathway is set to 2, which is
derived by log10 [adjusted p-value], with the Benjamini-Hoch-
berg corrected p-value 6 0.01.
5.11. Hierarchical clustering
Unsupervised 2-way hierarchical clustering was performed to
associate the expression pattern of the network-signature with
clinical parameters, such as ER status, lymph node inﬁltration,
and pathological grade. The default parameter and Pearson corre-
lation in dChip software was used to for hierarchical clustering.
Chi-square test was performed to evaluate whether patients with
different clinical phenotypes can be classiﬁed into different cluster
based on the expression pattern of network-signature.
5.12. Gene set enrichment analysis (GSEA)
GSEA software was used to quantitatively characterize the
expression pattern of network-signature between binary clinical
status, such as ER() vs. ER(+), high vs. low grade, poor vs. good
prognosis. The a priori established gene sets contains the net-
work-signature and 99 gene sets randomly selected from U133A
chip, each with the equal number of genes of the network-signa-
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parametric Kolmogorov–Smirnov test to calculate an enrichment
score and thus determine whether a speciﬁc gene set is differen-
tially expressed between the binary status of a phenotype. The ran-
domly selected gene sets are used here as controls to determine
whether any potential phenotypic association is unique to net-
work-signature.5.13. Survival analysis
BRB-Array Tools were used for time-to-event data analysis,
which is referred here as ‘‘survival analysis”. The survival data
most relevant to the prognosis of BC patients is the time of recur-
rence or distant metastasis. Two survival analysis tools in the
BRB-Array software implemented with Cox’s proportional hazards
model were used [53]. The ‘Survival Analysis Prediction Tool’
develops a gene expression based predictor of survival risk group.
The survival risk groups were constructed using the supervised
principal component method [53]. This method used a Cox pro-
portional hazards model to relate survival time to k ‘‘super-gene”
expression levels, where k = 2 in the current analysis. The ‘‘super-
gene” expression levels are the ﬁrst k principal component linear
combinations of expression levels of the subset of genes that are
univariately correlated with survival. The p -value criterion for
gene selection is set at 0.999, so that all of the genes in net-
work-signature are used in computing the principle component.
To compute a prognostic index for a patient whose expression
proﬁle is described by a vector x of log expression level, the fol-
lowing steps were performed. First the components of the vector
x corresponding to the genes that were selected for use in com-
puting the principal components are identiﬁed. Then the k princi-
pal components are computed. These are linear combinations of
the components of x, with the weights of each linear combination
having been determined from the principal component analysis
described above. Finally, the weighted average of these k princi-
pal component values is computed, using as weights the regres-
sion coefﬁcients derived from the k-variable Cox regression
described above. This computation provides a prognostic index
for a patient with a log expression proﬁle given by a vector x.
A high value of the prognostic index corresponds to a high value
of hazard of death, and consequently a relatively poor predicted
survival. Two-risk groups are predicted and leave-out-one meth-
od was used for cross validation. The prognostic index for the
omitted patient was ranked relative to the prognostic index for
the patients included in the cross-validated training set. The
left-out patient is placed into a risk group based her percentile
ranking, and the cut-off percentile is set at 50% for current anal-
ysis. This leave-one out analysis was repeated n times (n = sample
size), leaving out a different patient each time. It is important to
note that the risk group for each case was determined based on a
predictor that did not use that case in any way in its construc-
tion. Finally, Kaplan–Meier survival curve is plotted for the cases
predicted to have above or below average risk. Log rank test is
performed by 100 permutations and the criterion for signiﬁcance
is set at p < 0.05.Acknowledgments
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